Imatinib: A designer drug, another cutaneous complication

Clinical and Experimental Dermatology

Volumn 34, Issue 5, 2009, Pages 603-604

  Dickens, E ^a   Lewis, F ^a   Bienz, N ^a  

^a WEXHAM PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ALLOPURINOL; BCR ABL PROTEIN; IMATINIB; STEROID; VITAMIN D;

ADULT; ARTICLE; BACKACHE; BLOOD; BLOOD EXAMINATION; CANCER REGRESSION; CASE REPORT; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG CONTRAINDICATION; DRUG ERUPTION; DRUG INDUCED DISEASE; FINGER NAIL; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HYPERKERATOSIS; JOINT; LABORATORY TEST; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MYELOPROLIFERATIVE DISORDER; NAIL DYSTROPHY; NECK PAIN; NEUTROPHIL; ONYCHOLYSIS; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PSORIASIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NAIL DISEASES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PSORIASIS; PYRIMIDINES;

EID: 66449130074     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2009.03250.x     Document Type: Article

References (10)

1. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Eng J Med 2001 344 : 1031 7.
2. Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol 2006 5 : 228 31.
3. Valeyrie L, Bastuji-Garin S, Revuz J et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukaemias: a prospective study of 54 patients. J Am Acad Dermatol 2003 48 : 201 6.
4. Shimizu K, Kuroda H, Kida M et al. Psoriasis vulgaris exacerbated by imatinib therapy in chronic myelogenous leukaemia. Rinsho Ketsueki 2005 46 : 1152 5.
5. Woo SM, Huh CH, Park KC, Youn SW. Exacerbation of psoriasis in a chronic myelogenous leukaemia patient treated with imatinib. J Dermatol 2007 34 : 724 6.
6. Miyagawa S, Fujimoto H, Ko S et al. Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour. Br J Dermatol 2002 147 : 406 7.
7. Deguchi N, Kawamura J, Shimizu A et al. Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia. Br J Dermatol 2006 154 : 1216 18.
8. Krane JF, Murphy DP, Gottlieb AB et al. Increased dermal expression of platelet-derived growth factor receptors in growth activated skin wounds and psoriasis. J Invest Dermatol 1991 96 : 983 6.
9. Yamamoto T, Katayama I, Nishioka K. Possible contribution of stem cell factor in psoriasis vulgaris. J Dermatol Sci 2000 24 : 171 6.
10. Leder C, Ortler S, Seggewiss R et al. Modulation of T-effector function by imatinib at the level of cytokine secretion. Exp Hematol 2007 35 : 1266 71.